A strong performer from today's afternoon trading session is Moderna, whose shares rose 1.7% to $183.5 per share. For those of you thinking about investing in the stock, here is a brief look at the company's fundamentals.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. The company belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) ratio of 4.07. In contrast, Moderna has a trailing 12 month P/E ratio of -93.7 and a P/B ratio of 28.6.
P/B ratios are calculated by dividing the company's market value by its book value. The book value refers to all of the company's tangible assets minus its liabilities -- meaning that intangibles such as intellectual property, brand name, and good will are not taken into account. Traditionally, a P/B ratio of around 1 shows that a company is fairly valued, but owing to consistently higher valuations in the modern era, investors generally compare against sector averages.
Moderna has moved None% over the last year compared to None% for the S&P 500 — a difference of None%. Moderna has a 52 week high of $241.99 and a 52 week low of $115.03.
